FDA Advisory Committee Unanimously Recommends Moderna's mRNA Flu Vaccine

In a landmark regulatory milestone for respiratory immunization, the Food and Drug Administration’s top vaccine advisory committee has unanimously recommended the approval of the first mRNA-based seasonal influenza vaccine. On June 18, 2026, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of Moderna’s investigational shot, known as mRNA-1010 or mFlusiva, outweigh its risks for adults aged 50 to 64. In a separate 9-0 vote, the panel endorsed the vaccine for adults 65 and older. The unanimous outcome clears a critical hurdle for a vaccine that faced a highly unusual and turbulent regulatory review earlier this year, setting the stage for a potential rollout ahead of the 2026–2027 flu season.[1][2]

The introduction of messenger RNA technology to seasonal flu prevention represents a fundamental shift in how the United States prepares for annual epidemics. For decades, the majority of influenza vaccines have been manufactured by propagating viruses in chicken eggs or cell-based cultures—a process that takes up to six months and can inadvertently cause the virus to mutate. These "adaptive mutations" often lead to a mismatch between the vaccine and the circulating flu strains, significantly reducing the shot's effectiveness. By contrast, mRNA platforms use lipid nanoparticles to deliver genetic instructions directly to the body's cells, teaching them to produce the hemagglutinin proteins that trigger an immune response. This egg-free process cuts manufacturing time down to two or three months, allowing health officials to select target strains much closer to the start of the flu season and theoretically improving the vaccine's accuracy.[3][6]

The committee’s endorsement was anchored by robust clinical data from Moderna’s Phase 3 FLUENT trial, which was recently published in the New England Journal of Medicine. The double-blind, active-controlled study enrolled 40,703 participants aged 50 and older across 11 countries during the 2024–2025 flu season. Half of the participants received the mRNA-1010 vaccine, while the other half received a licensed, standard-dose seasonal flu shot. The primary objective was to determine if the mRNA platform could not only match but exceed the protection offered by traditional vaccines. According to the trial data, mRNA-1010 successfully met all prespecified sequential success criteria, achieving noninferiority, superiority, and higher-level superiority relative to the standard-dose comparator.[3][4]

When quantified, the efficacy gains demonstrated by the mRNA platform were substantial. The trial revealed a relative vaccine efficacy of 26.6% against protocol-defined, laboratory-confirmed influenza-like illness caused by either influenza A or B strains. This means that participants who received the mRNA shot were 26.6% less likely to contract a symptomatic flu infection than those who received the traditional standard-dose vaccine. Furthermore, the protection appeared to scale against more severe outcomes. When researchers looked at higher-level healthcare utilization—specifically emergency room visits, hospital admissions, and urgent care appointments—the relative efficacy of the mRNA vaccine rose to 47.9%. Strain-specific estimates remained consistent across the board, showing strong protection against A/H1N1, A/H3N2, and B/Victoria lineages.[3][4][6]

For adults aged 65 and older, the regulatory pathway relies on a different set of clinical benchmarks. Because older adults typically experience a natural decline in immune function, the standard of care for this demographic often involves high-dose or adjuvanted vaccines rather than standard-dose shots. To secure accelerated approval for this vulnerable cohort, Moderna conducted a separate Phase 3 immunobridging study comparing mRNA-1010 directly against a licensed high-dose influenza vaccine. The results indicated that the mRNA vaccine elicited superior immune responses—measured by the concentration of neutralizing antibodies in the blood—relative to the high-dose comparator across all four matched strains. Researchers also noted that the mRNA platform appeared to produce a longer-lasting immune response, with elevated antibody titers sustained at the six-month mark.[3][4]

While the efficacy data proved compelling, the VRBPAC panel also closely scrutinized the vaccine's safety profile, drawing on an integrated summary of more than 71,000 participants across multiple late-stage trials. The data showed that mRNA-1010 carries a higher rate of reactogenicity—expected, temporary physical reactions to the injection—than traditional flu shots. For instance, 65.8% of mRNA recipients reported injection-site pain, compared to just 29.8% in the comparator group. Systemic reactions like fatigue, headache, and muscle aches were also more common. However, FDA reviewers emphasized that these events were largely transient and mild to moderate in severity. Crucially, the pooled safety analysis identified no adverse event patterns indicative of a broader safety signal, and reviewers explicitly noted that no cases of myocarditis or pericarditis were linked to the mRNA vaccine.[3][4]

The unanimous vote stands in stark contrast to the vaccine's precarious position just a few months prior. In February 2026, the FDA’s Center for Biologics Evaluation and Research (CBER)—then under the direction of Dr. Vinay Prasad—issued a highly unusual "refuse-to-file" letter to Moderna, effectively halting the review process before it began. The agency's initial objection centered on the design of the Phase 3 trial, specifically arguing that the standard-dose seasonal flu vaccine used in the comparator arm did not represent the best available standard of care for older adults. The decision sparked immediate backlash within the scientific community, with critics arguing that the agency was retroactively changing the agreed-upon regulatory parameters for the trial.[2][6]

Following intense public scrutiny and internal debate, the FDA reversed its stance two weeks later, accepting a revised filing from Moderna and placing the vaccine back on track for a 2026 approval. Dr. Prasad subsequently departed the agency in April. By the time the VRBPAC briefing documents were released in mid-June, the FDA's tone had shifted dramatically. Agency reviewers explicitly stated that they found "no major deficiencies" in Moderna’s application, directly undercutting the basis of the earlier refuse-to-file letter. The briefing documents acknowledged the comparator debate but ultimately deferred to the advisory committee to weigh whether the robust relative efficacy and immunogenicity data were sufficient to support licensure across both age brackets.[2][3][6]

In keeping with the rigorous standards of an evidence-pack review, FDA staff and committee members highlighted several transparent gaps in the current clinical data. The most prominent limitation is that the efficacy data for mRNA-1010 is currently drawn from only a single influenza season (2024–2025). Because flu strains and vaccine effectiveness fluctuate wildly from year to year, long-term performance remains an open question. Additionally, reviewers noted that the vaccine's efficacy has not yet been definitively established in highly immunocompromised individuals or very frail older adults—populations that bear a disproportionate burden of severe flu complications. There is also a lack of comprehensive data regarding the co-administration of mRNA-1010 with other routine respiratory immunizations, such as updated COVID-19 or RSV vaccines.[3][6]

The push to modernize influenza vaccines carries immense public health implications. Despite widespread availability of traditional shots, seasonal flu remains a persistent and deadly threat. During the 2025–2026 season, the Centers for Disease Control and Prevention estimated that influenza caused tens of millions of illnesses, hundreds of thousands of hospitalizations, and tens of thousands of deaths in the United States alone. Public health officials have long warned that the variable performance of egg-based vaccines—which often hover around 40% to 50% effectiveness, and sometimes drop much lower during mismatch years—leaves the population vulnerable. An agile mRNA platform that can be rapidly reformulated to match late-emerging strains could drastically reduce this annual burden and provide a critical bulwark against future pandemic-level antigenic shifts.[5][6]

With the VRBPAC’s unanimous endorsement secured, the FDA is expected to make its final approval decision by the Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026. While the agency is not strictly bound by advisory committee votes, it rarely diverges from a unanimous recommendation. If approved, the vaccine will still need a formal recommendation from the CDC’s Advisory Committee on Immunization Practices (ACIP) before it can be widely distributed and covered by insurance. Moderna has indicated that, pending these final regulatory clearances, it is prepared to launch mFlusiva in time for the upcoming 2026–2027 respiratory virus season, offering older adults a fundamentally new tool in the fight against seasonal flu.[1][2][6]